We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

ZoBio and Actelion Enter into Drug Discovery Collaboration


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "ZoBio and Actelion Enter into Drug Discovery Collaboration"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

Under the agreement, ZoBio will apply its proprietary TINS technology to screen a library of drug fragments for specific binding to the desired conformation of the target. When successful, ZoBio will use a variety of biophysical methods, including its novel NMR-based structural biology, to validate and provide insight into the binding mechanism of the ligands.

Gregg Siegal, CSO of ZoBio said “We are proud that Actelion, a company with such success in bringing innovative drugs to the market, has selected ZoBio as a partner. We feel that this collaboration has a great chance to succeed where others have failed.”

Advertisement